News

AASLD: HCV cure associated with reduction in all-cause mortality

Posted on: 18/11/2015 - 22:05

SAN FRANCISCO – Sustained virologic response (SVR) in patients with hepatitis C virus (HCV) infection is associated with large reductions in all-cause mortality and appears to eliminate liver-related...

Field of Interest: Gastroentero...

Type: News Item

Riociguat deemed suitable for PAH in connective tissue disease

Posted on: 18/11/2015 - 20:50

SAN FRANCISCO – Phase III clinical trial experience in using riociguat indicates that the drug is just as safe and effective in treating pulmonary arterial hypertension associated with connective...

Field of Interest: Rheumatology

Type: News Item

AASLD: Pilot study shows value of response-guided therapy for HCV GT1b

Posted on: 18/11/2015 - 20:50

SAN FRANCISCO – Response-guided therapy using all-oral, triple direct-acting antiviral (DAA) therapy appears useful for shortening the duration of treatment in noncirrhotic patients with hepatitis C...

Field of Interest: Gastroentero...

Type: News Item

Triple therapy less effective than combination therapy for rheumatoid arthritis

Posted on: 18/11/2015 - 20:06

SAN FRANCISCO – Triple therapy for rheumatoid arthritis using methotrexate, sulfasalazine, and hydroxychloroquine is less effective than the combination of tumor necrosis factor inhibitor and...

Field of Interest: Rheumatology

Type: News Item

Real-world use of triple therapy for RA differs from clinical trial use

Posted on: 18/11/2015 - 19:33

SAN FRANCISCO – Triple therapy for rheumatoid arthritis has shone in clinical trials, but its adoption by rheumatologists in the trenches of patient care has been lukewarm. The challenges facing...

Field of Interest: Rheumatology

Type: News Item

Targeting IL-6 effective in RA poor responders to anti-TNF inhibitors

Posted on: 18/11/2015 - 19:22

SAN FRANCISCO – Sarilumab, an investigational monoclonal antibody directed against the IL-6 receptor, demonstrated efficacy at two different dose levels, compared with placebo, in patients with...

Field of Interest: Rheumatology

Type: News Item

Elevated liver cancer risk after HCV cure may justify surveillance

Posted on: 18/11/2015 - 18:46

SAN FRANCISCO – The risk of hepatocellular carcinoma remains sufficiently high in some subgroups who have achieved sustained virologic response to treatment to justify continued cancer surveillance,...

Field of Interest: Gastroentero...

Type: News Item

Investigational hepatitis B therapy shows activity in proof-of-concept study

Posted on: 18/11/2015 - 17:18

SAN FRANCISCO – NVR 3-778, an experimental hepatitis B virus (HBV) core inhibitor, showed substantial activity and was well tolerated in an initial phase Ib study presented as a late-breaker at the...

Field of Interest: Gastroentero...

Type: News Item

Transplant waiting-list registrations dropped after direct acting–antiviral approval

Posted on: 18/11/2015 - 14:10

SAN FRANCISCO – The number of new waiting-list registrations for liver transplantation among patients with hepatitis C virus declined significantly after the introduction of second-generation...

Field of Interest: Gastroentero...

Type: News Item

Baricitinib shows encouraging phase III results in RA

Posted on: 18/11/2015 - 13:54

SAN FRANCISCO – Baricitinib, an investigational oral investigational JAK 1/2 inhibitor, was significantly superior to adalimumab and to placebo in the treatment of patients with active rheumatoid...

Field of Interest: Rheumatology

Type: News Item

« first
‹ previous
…
36
37
38
39
40
41
42
43
44
…
next ›
last »

Newsletters

Stay informed on our latest news!

You are here

Newsletters

Latest Newsletters